| abstract |
The present invention relates to corticotropin releasing factor (CRF) agonists of the formula I and their mammalian psychiatric disorders and neurodegenerative disorders, anxiety related disorders, accidental stress disorder, supranuclear palsy and nutritional disorders, as well as immunological, cardiovascular and cardiovascular disorders. wherein A and B are N or substituted CH; D is an aryl or heteroaryl group attached through an unsaturated carbon atom; X is a substituted -CH 2 - or -NH- group, -O- or -S (O) n -, wherein n is 0, 1 or 2; R1 is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, arylsulfonyl or heteroarylsulfonyl; R2 is optionally substituted alkyl, alkenyl, alkynyl or cycloalkyl, -CN, -CF3 or C2F5; R3 is halogen, cyano, alkyl, cycloalkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, alkylamino, dialkylamino or optionally substituted phenyl. are also pharmaceutical compositions containing the above compounds. HE |